Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

ESMO Calls for Cancer to Remain a Flagship Priority in the...

Ogkologos - 5 Νοεμβρίου, 2025

Long-Term Follow-Up Confirms a Sustained Reduction in Deaths from Prostate Cancer...

Ogkologos - 4 Νοεμβρίου, 2025

ESMO Award for Immuno-Oncology 2025 Recipient Announced

Ogkologos - 4 Νοεμβρίου, 2025

Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death...

Ogkologos - 3 Νοεμβρίου, 2025

FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with...

Ogkologos - 30 Οκτωβρίου, 2025

Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active...

Ogkologos - 29 Οκτωβρίου, 2025

EMA Recommends Extension of Indications for Sugemalimab

Ogkologos - 28 Οκτωβρίου, 2025

Marking Breast Cancer Awareness Month 2025, ESMO Calls for Increasing Awareness...

Ogkologos - 27 Οκτωβρίου, 2025

FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma

Ogkologos - 27 Οκτωβρίου, 2025

Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated...

Ogkologos - 24 Οκτωβρίου, 2025

1...343536...440 Σελίδα 35 από 440

MOST POPULAR

Taking Time for the Everyday Things in 2024

29 Δεκεμβρίου, 2023

Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once...

26 Σεπτεμβρίου, 2024

FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma

8 Ιανουαρίου, 2021

Scientists Focus on Fusion Proteins in Childhood Cancers

4 Αυγούστου, 2020

Φόρτωση περισσοτέρων

ESMO Calls for Cancer to Remain a Flagship Priority in the...

Long-Term Follow-Up Confirms a Sustained Reduction in Deaths from Prostate Cancer...

ESMO Award for Immuno-Oncology 2025 Recipient Announced

Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death...

FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with...

Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active...

EMA Recommends Extension of Indications for Sugemalimab

Marking Breast Cancer Awareness Month 2025, ESMO Calls for Increasing Awareness...

FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma

Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated...

MOST POPULAR

Taking Time for the Everyday Things in 2024

Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once...

FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma

Scientists Focus on Fusion Proteins in Childhood Cancers

HOT NEWS

Excellence in cancer research nursing: Celebrating innovation during tough times

ESMO Calls for Cancer Care Safeguards in the EU’s Health Crisis...

ETV6 Protein Could Be an Important Target for Ewing Sarcoma Treatment

Temporary Interruption of Endocrine Therapy for Pregnancy, Including Use of Fertility...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ